Welcome to our dedicated page for Scpharmaceutical SEC filings (Ticker: SCPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for scPharmaceuticals Inc. (SCPH) provides a detailed regulatory record of the company’s life as a public issuer and its eventual acquisition by MannKind Corporation. As a Nasdaq-listed company with common stock registered under Section 12(b) of the Exchange Act, scPharmaceuticals filed periodic reports and numerous current reports on Form 8-K documenting material events, financing arrangements, and strategic transactions.
For investors and researchers, key filings include annual and quarterly reports that describe product revenues from FUROSCIX, research and development spending, and selling, general and administrative expenses, along with discussions of risks and business strategy. Current reports on Form 8-K capture important milestones such as FDA approval of an expanded FUROSCIX indication for chronic kidney disease, business updates around the FUROSCIX franchise, and the company’s participation in credit facilities and revenue participation agreements.
Filings from 2025 are particularly important for understanding the change in control. A Form 8-K dated August 25, 2025 describes the Agreement and Plan of Merger with MannKind Corporation, while a Form 8-K dated October 7, 2025 details the completion of the tender offer and merger, the conversion of scPharmaceuticals shares into cash plus a non-tradable contingent value right, and the company’s status as a wholly owned subsidiary of MannKind. The same filing explains the request to Nasdaq to file a Form 25 to remove SCPH from listing and registration, and notes the intention to file a Form 15 to terminate registration and suspend reporting obligations.
The Form 25 filed on October 7, 2025 by The Nasdaq Stock Market LLC formally notifies the SEC of the removal of scPharmaceuticals’ common stock from listing and registration under Section 12(b) of the Exchange Act. Together, these documents trace SCPH’s transition from a stand-alone public company to a private subsidiary within MannKind’s corporate structure. On Stock Titan, AI-powered tools can help users quickly interpret these filings by summarizing complex language, highlighting items related to the merger, delisting, financing agreements, and other material changes that shaped scPharmaceuticals’ regulatory history.